Cells expressing elevated levels of allelic variants of human glutathione S-transferase P1 (GSTP1) and/or efflux transporters, MRP1 or MRP2, were used to evaluate the role of GSTP1-1 in cisplatin resistance. These studies revealed that GSTP1-1 confers low-level resistance (1.4-to 1.7-fold) to cisplatin-induced cytotoxicity in MCF7 cells. However, expression of MRP1 (MCF7 cells) or MRP2 (HepG2 cells) failed to augment or potentiate GSTP1-1-mediated resistance in either cell line. To understand the mechanism by which variants of GSTP1-1 confer resistance to cisplatin, their relative abilities to catalyze conjugation of cisplatin with glutathione were examined. Enzymes encoded by all three alleles tested, GSTP1a (I 104 A 113 ), GSTP1b (V 104 A 113 ), and GSTP1c (V 104
Introduction
Cisplatin [cis-diamminedichloroplatinum (II)] is one of several platinum-containing compounds used for the treatment of a variety of malignancies including ovarian, testicular, and lung cancers (1) . It is generally accepted that cisplatin initiates cell death primarily through the formation of intrastrand cross-links, the majority of which involve neighboring purine bases (2) . Accumulation of these adducts can inhibit DNA replication and transcription, triggering cell cycle arrest and apoptosis (3 -5) . A major limitation of cisplatin treatment is the acquisition of drug resistance. Several molecular and biochemical mechanisms have been implicated in this resistance including decreased cellular uptake, enhanced cellular inactivation, increased tolerance to DNA damage, and increased cellular efflux (6) . The association between elevated cellular levels of glutathione (GSH) and cisplatin resistance has lead to the suggestion that inactivation of cisplatin can occur through conjugation with GSH (7, 8) . Indeed cisplatin has been shown to complex nonenzymatically with GSH (9 -12) and some of the resulting platinum-GSH conjugates (Pt-SG) have been characterized (9, 11, 12) .
Elevated glutathione S-transferase P1-1 (GSTP1-1) expression has been associated with resistance to cisplatinbased chemotherapy and with cellular resistance to cisplatin cytotoxicity in many experimental systems (13 -17) . The finding that GSTP1-1 can enhance the rate of Pt-SG formation suggests a potential catalytic mechanism for GSTP1-1-associated cisplatin resistance (18) . In addition to the most common allelic variant of human GSTP1, GSTP1a (I 104 A 113 ), at least three other allelic variants have been identified including GSTP1b (V 104 A 113 ) and GSTP1c (V 104 V 113 ; refs. 19, 20) . The particular alternative allelic form(s) expressed is potentially important as the variants are reported to differ in their catalytic efficiencies toward the conjugation with GSH of several environmental toxins and anticancer drugs-catalytic differences that lead to apparent variations in protection afforded by the GSTP1-1 variants against the toxicities of several compounds including the diol-epoxides of polycyclic aromatic hydrocarbons and anticancer agents such as thiotepa and 4-hydroxyifosphamide (14, 20 -23) . Moreover, studies evaluating the distribution of the GSTP1 polymorphisms in the population have shown a relationship between expression of specific GSTP1-1 variants and susceptibility to a variety of cancers (24, 25) . Lastly, expression of GSTP1 allelic variants in bacterial cells yielded different levels of protection from cisplatin toxicities (14) .
The primary goals of the studies described herein were to determine if forced expression of GSTP1-1 could confer resistance to cisplatin in model MCF7 cells and, if so, whether the mechanism of GSTP1-1-mediated resistance involves catalysis of cisplatin/GSH conjugation. Additionally, three variants of GSTP1-1 were examined to determine whether they differed in their relative catalysis of Pt-SG formation and if expression of these alternative allelic variants would be associated with differential protection from cisplatin cytotoxicity.
However, as suggested by Ishikawa (26) , complete detoxification may not be attained by GSH conjugate (GS-X) formation alone; rather, this may require active efflux of the GS-X formed intracellularly. Indeed our laboratory has shown that removal of GS-X is often required to fully achieve GST-associated resistance (27 -29) . Accordingly, in the studies presented, we examined whether coexpression of GS-X efflux pumps, MRP1 (MCF7 cells) or MRP2 (HepG2 cells), would augment or potentiate GSTP1-1-mediated resistance to cisplatin cytotoxicity.
The results outlined below indicate that although variants of GSTP1-1 can indeed confer low-level resistance to cisplatin in some cell lines, the rates of GSTP1-1-mediated catalysis are extremely slow, suggesting that alternative mechanisms are needed to explain GSTP1-1-associated resistance to cisplatin.
Materials and Methods
Cell Lines and Tissue Culture Parental MCF7 (MCF7/WT) and HepG2 cell lines and their transgenic derivatives were cultured in DMEM (MCF7 cells) or DMEM/F-12 (HepG2 cells) containing 10% fetal bovine serum. MCF7/WT cells possess extremely low endogenous GST activity and MRP1 expression (27) . Transgenic cell lines engineered to express human GSTP1a-1a (MCF7/P1a-7) and/or MRP1 (MCF7/MRP1-10 and MRP1-10/P1a-4) have been developed, characterized, and cultured as described previously (30, 31) . HepG2 parental cells expressing MRP2 were stably transfected with the doxycycline-repressible VP16 transactivator fusion gene (HepG2/tTA) and a doxycycline-repressible GSTP1a-1a expression vector (HepG2/k3) as described (29) . In addition, cDNAs encoding the human allelic variants, GSTP1b and GST1c (kindly supplied by Dr. Francis AliOsman, Duke University), were subcloned into pLHCX. Packaging cells (PA317) were transfected with the pLHCX/ GSTP1b and pLNCX/GSTP1c vectors and the viral particle containing supernatants were used to stably transduce parental MCF7 cells as described previously (30, 31) . Clones stably expressing allelic variants of GSTP1 were selected in 0.4 mg/mL hygromycin. Transgenic cells were maintained in selecting drugs [0.2 mg/mL hygromycin (MCF7/P1a-7, MCF7/P1b-9 and -18, and MCF7/P1c-4 and -27), 1 mg/mL G418 (MCF7/WT-LN, MCF7/MRP1-10, and HepG2/tTA), or both drugs (MRP1-10/P1a-4 and HepG2/ k3)] until just before experiments at which time selecting drugs were removed from the medium. For some experiments, GSTP1a-1a expression in HepG2/k3 was repressed by culturing in 1 Ag/mL doxycycline.
Cytotoxicity Determinations Cytotoxicity was determined using the sulforhodamine B microtiter plate assay as described (32) . Cells were plated at a density of 300 per well (MCF7 derivatives) or 1,200 per well (HepG2 derivatives) in 96-well plates. Twenty-four hours later, the cells were exposed to varying concentrations of cisplatin, doxorubicin (Sigma-Aldrich), or vehicle control for 1 or 24 h in medium containing 10% fetal bovine serum. The medium was subsequently replaced and the plates were incubated 5 to 7 days, fixed, and stained. In some experiments, MRP2 was inhibited with 20 or 50 Amol/L MK571 (Alexis), which was added to the medium 15 min before introduction of cisplatin or doxorubicin and continued throughout the drug exposure. Cytotoxicities are expressed as IC 50 High-Performance Liquid Chromatography/Tandem Mass Spectrometry Analysis of Pt-SG
The characterization of Pt-SG was accomplished as follows. Pt-SG were formed by incubating equimolar (3 mmol/L) cisplatin and GSH in 10 mmol/L sodium phosphate buffer (pH 7.5) containing 150 mmol/L NaCl for 30 min at 25jC. The reaction mixture (25 AL) was separated, before entering the electrospray source, by highperformance liquid chromatography (HPLC) using a Beckman Ultrasphere C 18 reverse-phase column (25 cm Â 4.6 mm, 5 mm; Beckman Coulter) and isocratic elution in 15 mmol/L formic acid at 0.7 mL/min. Approximately 95% was sent to a diode array detector and 5% was diverted to a Micromass Quattro II mass spectrometer (Waters) equipped with a z-spray and triple quadrupole analyzer. Peaks corresponding to cisplatin, mono-platinum/mono-GSH conjugate (Pt 1 -SG, m/z 572), and bis-platinum/mono-GSH conjugate (Pt 2 -SG, m/z 835) were eluted from the HPLC column at 3.6, 4.7, and 4.2 min, respectively. Tandem mass spectrometry (MS) analysis was achieved in positive ion mode with the following instrument settings: capillary voltage, 3.50 kV; cone voltage, 35 V; and collision energy 15 eV.
Recombinant GSTP1-1 Variants Expression and purification of recombinant GSTP1a-1a have been described previously (30) . The coding regions of GSTP1b and GSTP1c were amplified by PCR and inserted into pOXO4. Expression and purification of the GSTP1-1 variants were achieved as follows. Briefly, BL21 Star competent Escherichia coli (Invitrogen) were transformed with the appropriate plasmid vector and expression was induced using IPTG. Bacteria were centrifuged, washed with PBS, resuspended in lysis buffer [50 mmol/L Tris (pH 7.5) and 50 mmol/L EDTA], and sonicated. GSTP1-1 were purified using GSH-agarose affinity chromatography and final preparations were subjected to high-performance centrifugal concentration (Orbital Biosciences). The purities of GSTP1-1 variants were confirmed by SDS PAGE. Protein concentrations and activities for the GST preparations were determined as described (33, 34) . Specific activities were
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GSTP1a-1a, 91 units/mg; GSTP1b-1b, 42 units/mg; and GSTP1c-1c, 38 units/mg, where units are defined as micromolar 1-chloro-2,4-dinitrobenzene conjugated with GSH per minute at 25jC (34) .
Analysis of Nonenzymatic and GSTP1-1-Catalyzed Pt-SG Formation
Analysis of Pt-SG formation was accomplished as follows. Reaction mixtures contained 1 mmol/L CDDP and 2 mmol/L GSH in the presence or absence of 33 units/ mL recombinant GSTP1a-1a, GSTP1b-1b, or GSTP1c-1c in 10 mmol/L sodium phosphate (pH 6.8). Mixtures were incubated for 0, 2, or 60 min at 25jC, after which 30 AL was removed and analyzed by reverse-phase HPLC using the system and conditions described above. Elution was monitored at 260 nm: the peaks corresponding to cisplatin (3.7 min), Pt 1 -SG (4.7 min), and Pt 2 -SG (4.2 min) were identified and quantified by integrating the areas under the peaks. Relative rates of Pt 1 -SG formation were determined from quantified peak areas (4.7 min peaks) at 2 and 60 min with relative rates defined as [Pt 1 -SG formation of the test sample (FGST)] / [nonenzymatic Pt 1 -SG formation (-GST)]. Actual rates of cisplatin reactions with GSH were estimated from the rates of cisplatin depletion (Dconcentration cisplatin time -1 ) using quantified cisplatin peak areas (3.7 min peaks) obtained at 0, 2, and 60 min. Enzymatic rates were calculated by subtracting nonenzymatic (-GST) from enzymatic (+GST) cisplatin depletion data. Dividing these values by molar enzyme concentrations resulted in approximate enzymatic activity toward cisplatin conjugation expressed as time -1 .
Western Blot Analysis
Western blots for GSTP1-1 expression were prepared from whole-cell lysates as described previously (27) . For the analysis of phospho-c-Jun expression, MCF7 derivative cells were plated in 100 mm dishes at a density of 2.5 Â 10 6 per plate. Twenty-four hours later, cells were treated with 10, 25, 50, or 100 Amol/L cisplatin or vehicle control for the indicated times. Cells were washed with PBS and total cell extracts were prepared as described (27) . Immunoblot analysis of phospho-c-Jun was done using 25 Ag whole-cell lysate separated by 10% acrylamide SDS-PAGE. Proteins were transferred to a nitrocellulose membrane, blocked with a 5% milk solution, and incubated with a 1:500 dilution of polyclonal rabbit anti-phospho-c-Jun antibody (sc-7981; Santa Cruz Biotechnology) followed by a 1:4,000 dilution of goat horseradish peroxidase-conjugated antirabbit antibody. Bands corresponding to phospho-c-Jun were visualized by chemiluminescence. Equivalency of protein loading and transfer was established by staining the nitrocellulose membranes with Ponceau S.
Results

Expression of Allelic Variants of GSTP1 in MCF7 Cells and Their Role in Cisplatin Resistance
To determine the relative abilities of the variants of GSTP1-1 to influence cellular sensitivity to cisplatin, MRPpoor parental MCF7 cells (MCF7/WT) were stably transduced with expression vectors encoding the P1a, P1b, and P1c allelic variants of GSTP1. In addition, the MRP1-expressing transgenic derivative, MCF7/MRP1-10, was stably transduced with the GSTP1a-1a expression vector. Western blot analysis showed similar levels of GSTP1-1 protein expression in all six GST-transduced cell lines, Table 1 . GSTP1-1 expression in transduced MCF7 cell lines
P1a (I 104 A 113 ) + 300 F 28 3.3 F 0.3 * Cell lines designated MCF7/ were derived from parental MCF7/WT cells stably transduced with control vector (pLNCX, MCF7/WT-LN) or expression vectors encoding the P1a, P1b , or P1c alleles of human GSTP1 as indicated. MCF7/MRP1-10 cells were derived from MCF7/WT cells stably transduced with a human MRP1 expression vector. MRP1-10/P1a-4 cells were MCF7/MRP1-10 cells stably transduced with the GSTP1a expression vector. c GST activities were determined from whole-cell lysates and are expressed as nmol 1-chloro-2,4-dinitrobenzene conjugated min À1 mg À1 of total cellular protein. Mean F 1 SE of 6 to 11 independent determinations. b GSTP1-1 protein expression levels (Ag GSTP1-1/mg total cellular protein) were calculated by dividing 1-chloro-2,4-dinitrobenzene activity ( c ) by the specific activities of purified GSTP1-1 variants toward 1-chloro-2,4-dinitrobenzene. Mean F 1 SE of 6 to 11 independent determinations. whereas GSTP1-1 was undetectable in the parental MCF7/ WT or MCF7/MRP1-10 cells (Fig. 1) . The GST activities of the eight MCF7 cell lines are shown in Table 1 . Because MCF7/WT and/MRP1-10 cells have very little total GST, the activities of the transduced cell lines represent GSTP1-1 expression almost exclusively.
Cisplatin cytotoxicity was determined in the eight cell lines (Fig. 2) . To ensure ample opportunity for GST to detoxify cisplatin, cells were exposed to drug for 24 h (Fig. 2B and D) and 1 h ( Fig. 2A and C) . The IC 50 values determined from these experiments were used to calculate relative resistance ( Fig. 2A and B) . As shown, relative to empty vector transduced control cells MCF7/WT-LN (WT-LN), expression of all three alternative GSTP1 alleles, GSTP1a (MCF7/P1a-7), GSTP1b (MCF7/P1b-9 and -18), and GSTP1c (MCF7/P1c-4 and -27), conferred a modest but statistically significant 1.4-to 1.7-fold resistance to cisplatin cytotoxicity using both durations of drug exposure ( Fig. 2A and B) . Remarkably, however, there was no consistent relationship between relative resistance and the particular variant expressed or its level of expression (Table 1) . Similarly, coexpression of GSTP1a-1a with MRP1 (MRP1-10/P1a-4 cells) conferred a low-level resistance to cisplatin that was statistically significant in the 24 h exposure experiments (Fig. 2C and D) . However, also shown in Fig. 2C and D, expression of MRP1 alone (MCF7/MRP1-10) conferred no survival advantage over MRP-poor cells (MCF7/WT-LN) nor was MRP1 able to augment the level of resistance conferred by GSTP1a-1a alone (compare MRP1-10/P1a-4 with P1a-7; Fig. 2C and D) .
Can MRP2 Potentiate GSTP1-1-Mediated Resistance to Cisplatin?
The failure of MRP1 to influence cisplatin cytotoxicity ( Fig. 2C and D) was not entirely unexpected as previous 
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studies have generally found no association between MRP1 expression and cisplatin resistance (35, 36) . However, there is evidence supporting the role of MRP2 expression in cisplatin detoxification (37 -39) . To determine if MRP2 could potentiate or enhance GSTP1-1-associated cisplatin resistance, we did additional cytotoxicity studies using HepG2 cells, a cell line expressing MRP2 but not MRP1 (29) , engineered to conditionally express GSTP1a-1a. As summarized in Table 2 , expression of GSTP1a-1a (HepG2/k3 -doxycycline) conferred no survival advantage over control cells expressing little or no GST (HepG2/tTA and HepG2/k3 + doxycycline) when the cells were treated with cisplatin for 1 or 24 h. Moreover, inhibition of MRP2 with 20 or 50 Amol/L MK571 had no effect on cisplatin cytotoxicity in HepG2/k3 cells expressing GSTP1a-1a (Fig. 3) . Control experiments revealed that similar treatment of HepG2/k3 cells with 50 Amol/L MK571 resulted in 1.6-fold sensitization to doxorubicin cytotoxicity ( Supplementary Fig. S1 ), 1 suggesting that such treatment with MK571 effectively inhibits MRP2 function in HepG2 cells. Thus, in contrast to MCF7 cells, expression of GSTP1-1 failed to confer cisplatin resistance in HepG2 cells. Furthermore, expression of MRP2 neither conferred resistance (MK571 inhibition studies) nor potentiated GSTP1-1-mediated resistance to cisplatin ( Table 2) .
Catalysis of Cisplatin/GSH Conjugation by Variants of GSTP1-1 and Its Potential Role in Cisplatin Resistance
Nonenzymatic reactions with GSH and cisplatin were characterized by HPLC/MS as described in Materials and Methods. These reactions yielded two major products, the predominant one eluting at 4.7 min with a m/z of 572 and the other at 4.2 min with a m/z 835. Mass spectra of each species showed the characteristic isotopic distribution of platinum ( Fig. 4A and C) . Further analysis by collision-induced dissociation of the 572 parent ion yielded a fragmentation pattern (Fig. 4B ) consistent with the mono-platinum/mono-GSH structure (Pt 1 -SG) shown (Fig. 4A, inset) . The other species, m/z 835, yielded a collision-induced dissociation spectrum (Fig. 4D ) consistent with the bis-platinum/mono-GSH structure (Pt 2 -SG; Fig. 4C , inset) described previously by Bernareggi et al. (9) , although these data cannot rule out the alternative Pt 2 -SG structure proposed by Townsend et al. (12) . We were unable to detect any product consistent with the bis-GSH/mono-platinum adduct reported by Odenheimer and Wolf (40) and Ishikawa and Ali-Osman (11) . Only the dominant adduct, Pt 1 -SG, showed linear, time-dependent nonenzymatic and GSTP1-1-catalyzed formation; hence, analysis of this species was chosen for the following enzymatic studies.
Inclusion of purified recombinant GSTP1-1 (33 units) in reactions containing 1 mmol/L cisplatin and 2 mmol/L GSH (pH 6.8, 25jC) resulted in very modest but statistically significant increases in relative Pt 1 -SG formation after 2 and 60 min incubations for all three allelic variants of GSTP1 (Fig. 5) . The increases in relative Pt 1 -SG conjugation rates, over nonenzymatic rates, were greatest for GSTP1b-1b and GSTP1c-1c. When the nonenzymatic rates were subtracted from the data shown in Fig. 5 and the resulting relative GSTmediated conjugation rates are expressed as relative rates per milligram GSTP1-1, the GSTP1b-1b and GSTP1c-1c variants supported rates of conjugation that were 1.8-to 1.9-fold higher (80-90% increase) than the rate mediated by GSTP1a-1a. Despite these increased rates of conjugation mediated by GSTP1b-1b and GSTP1c-1c, no discernible differences in the sensitivities toward cisplatin cytotoxicity were observed among MCF7 cells expressing the three Figure 3 . Inhibition of MRP2 activity has no effect on cisplatin sensitivity of GSTP1a-1a-expressing HepG2 cells. Cytotoxicity of cisplatin was determined using the sulforhodamine B assay as described in Materials and Methods. HepG2/k3 cells were grown in the absence of doxycycline and express GSTP1a-1a (Table 2) (Fig. 2) . These data suggest that GSTP1-1 catalysis of Pt 1 -SG conjugate formation may not be the sole, or even major, determinant of cisplatin resistance associated with GSTP1-1 expression in MCF7 cells.
To further address this point, the actual enzymatic rates for GSTP1-1-mediated cisplatin conjugation were estimated from cisplatin depletion data as described in Materials and Methods. Under the conditions used (1 mmol/L cisplatin, 2 mmol/L GSH, 7.8-18.6 Amol/L GSTP1-1, pH 6.8, 25jC) the enzymatic rates for the three allelic variants ranged from 1.7 to 2.6 h -1 , an extremely slow rate, indeed, lending further support to the argument that GSTP1-1 catalysis of cisplatin conjugation is not likely to be a major determinant of cellular sensitivity to cisplatin.
Alternative Mechanisms of GSTP1-1-Mediated Cisplatin Resistance: Influence of GSTP1-1 Expression on c-Jun NH 2 -Terminal Kinase/Stress-Activated Protein Kinase Signaling Pathways Expression of GSTP1-1 is reported to interact with and modulate the activities of several signaling kinases and pathways (41 -43) , including the c-Jun NH 2 -terminal kinase (JNK)/stress-activated protein kinase (SAPK) pathways, which, in susceptible cells, influence cell survival and death (44 -46) . A comprehensive analysis of these pathways is beyond the scope of the present study; however, we were particularly interested in examining whether GSTP1-1 expression could modulate JNK-associated c-Jun phosphorylation, a signaling event linked to cisplatin-mediated apoptosis and cytotoxicity in several studies (44, 46, 47) . Using phospho-c-Jun levels as an indicator of activity in this signaling pathway, treatment of parental MCF7 cells with 100 Amol/L cisplatin resulted in a robust timedependent increase in phospho-c-Jun, whereas expression of GSTP1a-1a resulted in significant reductions of cisplatininduced phospho-c-Jun levels ( Supplementary Fig. S2 ).
1 In contrast to treatment with 100 Amol/L cisplatin, treatment at lower concentrations (10-50 Amol/L) showed very little difference between the two cell lines with respect to phospho-c-Jun increases. Hence, the significance of GSTP1-1-mediated attenuation of JNK activity observed at 100 Amol/L cisplatin is uncertain.
Discussion
In several published reports, increased expression of GSTP1-1 has been associated with cellular resistance to the DNA-damaging cancer drug, cisplatin (13 -15, 17) . The formation of GSH conjugates with cisplatin (Pt-SG) renders the drug unable to form DNA strand cross-links and hence is expected to significantly reduce its cytotoxicity. Thus, an obvious potential mechanism for GSTP1-1-associated resistance to cisplatin is via the catalysis of Pt-SG formation. Here, we have evaluated the role of human GSTP1-1 in cisplatin resistance: using purified variants of GSTP1-1, catalysis of Pt 1 -SG formation was examined, quantitative differences in catalysis of Pt 1 -SG formation between the variants were identified, and, using model transgenic cell lines expressing the alternative allelic variants of GSTP1, we asked whether these differences in catalysis would be associated with differences in cisplatin sensitivity. In addition, previous results from our laboratory have suggested that, because of product inhibition or residual toxicity of GSH conjugates, expression of GST is often insufficient to confer significant cellular protection from DNA-damaging electrophiles unless a GS-X efflux transporter is also expressed (27 -29) . Moreover, Pt-SG, although unable to form DNA strand cross-links, may retain some toxicities such as the inhibition of protein synthesis (11) . Thus, a secondary goal of the present study was to evaluate the potential contribution of GS-X transporters on cisplatin resistance.
We find that forced expression of GSTP1-1 in MCF7 cells confers low-level but statistically significant resistance to cisplatin cytotoxicity (Fig. 2) . Variants of GSTP1-1 enhance the rate of cisplatin conjugation with GSH (Pt 1 -SG formation) and the GSTP1b-1b and GSTP1c-1c variants are 80% to 90% more active in catalyzing these reactions than is the GSTP1a-1a variant. Despite these differences in catalytic activity, there are no discernible differences in cisplatin resistance conferred by expression of the alternative alleles ( Fig. 2A and B) , although the levels of GSTP1-1 expression are comparable among the transgenic clones (Table 1) . These data cast doubt on the importance of GSTP1-1-mediated catalysis of Pt 1 -SG formation as a mechanism of cisplatin resistance. More striking is the finding that the catalytic activities of GSTP1-1 variants toward cisplatin conjugation are extremely low at 1.7 to 2.6 h -1 (25jC, 1 mmol/L cisplatin, 2 mmol/L GSH, pH 6.8), values that are even less than the k cat of f14 h -1 , itself quite low, which can be calculated from the data of Goto et al. Cisplatin (1 mmol/L) and GSH (2 mmol/L) were incubated in the presence or absence of 33 units/mL GSTP1a-1a, GSTP1b-1b, or GSTP1c-1c at pH 6.8, 25jC. Aliquots were removed at 2 min (A) or 60 min (B) and Pt 1 -SG formation was quantified by HPLC analysis as described in Materials and Methods. Pt 1 -SG levels formed in the presence of GST were normalized to Pt 1 -SG formation in the absence of GST (-GST) and were expressed as relative Pt 1 -SG formation. Columns, mean of 6 to 18 independent experiments; bars, 1 SE. Pt 1 -SG formation was significantly higher in GSTP1-1 containing reactions than in control (-GST) reactions at both time points. *, P < 0.05; **, P < 0.01; Student's t test. Fig. 3 ) neither confers cellular resistance to cisplatin nor potentiates (or augments) GSTP1-1-mediated resistance to cisplatin. Together, these data suggest GSTP1-1 catalysis of Pt 1 -SG formation is very unlikely to have a significant effect on cellular sensitivity to cisplatin toxicity with or without the coexpression of GS-X efflux transporters.
Thus, although the studies described herein confirm that GSTP1-1 can confer cisplatin resistance in some cell lines, an alternative mechanism that does not involve catalysis of cisplatin/GSH conjugation is necessary to explain GSTP1-1-mediated resistance. There are several reports indicating that expression of GSTP1-1 can modulate the activities of multiple signaling pathways (41 -43) . A comprehensive analysis of these pathways is beyond the scope of the present work. Nevertheless, reports that GSTP1-1 may inhibit JNK/SAPK signaling were particularly interesting (41) : this is because cisplatin-induced activation of JNK signaling is implicated in increased apoptosis and cell death, whereas inhibition of JNK/SAPK is associated with resistance to cisplatin (44, 45) . These findings lead to the suggestion that JNK/SAPK pathways can play crucial roles in the execution of cisplatin-mediated cell death. To test the idea that GSTP1-1 may influence cellular sensitivity to cisplatin by interfering with JNK signaling, we examined changes in phosphorylated levels of the JNK substrate, c-Jun, on cisplatin treatment. Indeed, we found that, on exposure of cells to high concentration (100 Amol/L) cisplatin, expression of GSTP1-1 is associated with significant reductions in cisplatin-induced phospho-c-Jun levels ( Supplementary Fig. S2 ), 1 consistent with the suggestion that GSTP1-1 may mediate resistance by inhibition of the JNK pathway. However, as little difference in cisplatininduced phospho-c-Jun levels was observed between GSTP1-1-expressing and nonexpressing MCF7 cells at lower cisplatin concentrations, the significance of GSTP1-mediated attenuation of JNK signaling at 100 Amol/L cisplatin is uncertain.
The signaling events induced by cisplatin are many and complex. For example, in addition to JNK/SAPK, both extracellular signal-regulated kinase and p38 pathways are affected by cisplatin treatment and are reported to be influenced by GSTP1-1 (43) . Extracellular signal-regulated kinase activation, in particular, may oppose the apoptotic response associated with JNK/SAPK activation in cisplatintreated cells. Moreover, in some cells, in contrast or in addition to its role in cisplatin-induced apoptosis, JNK activation is implicated in protection from cisplatin toxicity via enhanced repair of DNA damage (48, 49) or by alternative mechanisms (50) . The balance and magnitude of these potentially opposing signaling events are very likely cell specific; hence, the net effect of GSTP1-1 expression on cisplastin sensitivity may well vary between cells of different origin. Another potential determinant of altered JNK signaling is the relative levels of JNK and GSTP1 expressed and, hence, the ratios of JNK:GSTP1 complex formed. Indeed, experiments using GSTP-deficient mice indicate that JNK signaling is constitutively increased in GstP1/P2
(À/À) animals (51) . In MCF7 cells, GSTP1-1 expression resulted in only 1.4-to 1.7-fold resistance to cisplatin (Fig. 2) , whereas, in other cell lines, in which the balance of opposing signaling pathways is shifted, inhibition of JNK or modulation of other signaling pathways by GSTP1-1 may have a relatively larger effect on cellular sensitivity to cisplatin toxicity. Regardless, based on enzymatic data presented herein, the expression of GSTP1-1 is not likely to have a major effect on cellular sensitivity to cisplatin via catalysis of Pt 1 -SG formation; rather, an alternative mechanism is required to explain the high level resistance to cisplatin associated with GSTP1-1 expression reported in some studies.
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